Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51

• Published in: Vaccine Vol. 26; no. 48; pp. 6151 - 6156
• Main Authors: Schuller, Elisabeth, Klade, Christoph S., Heinz, Franz X., Kollaritsch, Herwig, Rendi-Wagner, Pamela, Jilma, Bernd, Tauber, Erich
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 11.11.2008; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; Aging - immunology; Allergy and Immunology; Animals; Antibodies, Viral - biosynthesis; Antibodies, Viral - immunology; Antibody Specificity; Applied microbiology; Arachnids; Biological and medical sciences; Cercopithecus aethiops; Cross Reactions; ELISA; Encephalitis; Encephalitis Viruses, Tick-Borne - immunology; Enzyme-Linked Immunosorbent Assay; Enzymes; Female; Flavivirus; Fundamental and applied biological sciences. Psychology; Humans; IC51; Infections; Japanese Encephalitis Vaccines - immunology; Japanese encephalitis virus; JEV; Male; Microbiology; Middle Aged; Miscellaneous; Neutralising antibody; Neutralization Tests; Population; Primaries & caucuses; Standard deviation; TBEV; Vaccination; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Variance analysis; Vector-borne diseases; Vero Cells; Virology; Young Adult; United States > US; IC51; Vaccination; TBEV; JEV; Neutralising antibody; Flavivirus; ELISA; Immune response; Neutralizing antibody; Tick borne encephalitis group virus; Virus; Japanese encephalitis virus; Japanese encephalitis group virus; Flaviviridae; ELISA assay; Tick borne encephalitis virus; Humoral immunity; Inactivated strain
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2008.08.056

Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in Asia with a case fatality rate up to 35% and long-term sequelae up to 75%. This active-controlled, randomized, multi-centre, observer-blind, phase III trial investigated the neutralising antibody response to the new Japanese encephalitis (JE) vaccine IC51 in subjects with (N=81) and without (N=339) pre-existing tick-borne encephalitis (TBE) vaccine induced antibodies as determined by TBE enzyme-linked immunosorbent assay IgG (ELISA). Neutralising antibody response was statistically superior in TBE ELISA-positive subjects compared to TBE ELISA-negative subjects after the first (p<0.0001) but not after the second vaccination with IC51. Thus, pre-existing vaccine-induced TBE immunity enhances the neutralising JEV-specific antibody response after a single IC51 vaccination.